Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Observational × surufatinib × Clear all

Status

Sponsor Class

Study Type

Interventional 60 Observational 1 Expanded_access 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumor Grade 3 1

Interventions

Surveys and Questionnaires 454 Blood Specimen Collection 368 Surgical Procedures, Operative 131 Radiotherapy 126 Observation 121 Interviews as Topic 119 Drug Therapy 117 Gene Expression Profiling 114 Biopsy 99 Magnetic Resonance Spectroscopy 96 Immunohistochemistry 89 Data Collection 85 Polymerase Chain Reaction 75 Amplified Fragment Length Polymorphism Analysis 69 Specimen Handling 68 Microarray Analysis 65 Bevacizumab 63 Watchful Waiting 59 Magnetic Resonance Imaging 59 Neoadjuvant Therapy 58 Flow Cytometry 55 Nivolumab 51 Immune Checkpoint Inhibitors 51 Therapeutics 50 Reverse Transcriptase Polymerase Chain Reaction 45 pembrolizumab 44 Positron Emission Tomography Computed Tomography 41 Radiosurgery 40 Liquid Biopsy 40 Ultrasonography 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05973968 2023-08-04

Surufatinib in G3 Neuroendocrine Tumors

Qilu Hospital of Shandong University

Neuroendocrine Tumor Grade 3

Data powered by HemOnc (CC BY 4.0) Colophon ⚡